- Home
- VSTM vs KBDC Comparison
VSTM vs KBDC Comparison
Compare VSTM & KBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VSTM | KBDC |
|---|---|---|
| Founded | 2010 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.8M | 855.9M |
| IPO Year | 2011 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VSTM | KBDC |
|---|---|---|
| Price | $7.46 | $13.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $16.50 | $15.50 |
| AVG Volume (30 Days) | ★ 2.0M | 335.1K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 13.16% |
| EPS Growth | ★ 17.49 | N/A |
| EPS | N/A | ★ 0.85 |
| Revenue | ★ $30,914,000.00 | N/A |
| Revenue This Year | $282.64 | $193.84 |
| Revenue Next Year | $72.25 | $9.00 |
| P/E Ratio | ★ N/A | $15.58 |
| Revenue Growth | ★ 209.14 | N/A |
| 52 Week Low | $3.43 | $12.88 |
| 52 Week High | $10.82 | $15.87 |
Technical Indicators
Market Signals| Indicator | VSTM | KBDC |
|---|---|---|
| Relative Strength Index (RSI) | 55.75 | 43.00 |
| Support Level | $6.68 | $12.88 |
| Resistance Level | $7.86 | $14.20 |
| Average True Range (ATR) | 0.41 | 0.23 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 32.79 | 29.89 |
Price Performance
Historical ComparisonAbout VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About KBDC Kayne Anderson BDC Inc.
Kayne Anderson BDC Inc is an externally managed, closed-end, non-diversified management investment company that has elected to be regulated as a business development company, investing mainly in first-lien senior secured loans, with a secondary focus on unitranche and split-lien loans to middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation mainly through debt investments in middle-market companies.